Expertise in
21
conditions

Dr. Herbert B. Newton

Oncology
AdventHealth Medical Group Neuro Oncology At
2501 N Orange Ave Ste 286, 
Orlando, FL 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth
Expertise in
21
conditions
AdventHealth Medical Group Neuro Oncology At
2501 N Orange Ave Ste 286, 
Orlando, FL 

Overview

Herbert Newton is an Oncologist practicing medicine in Orlando, Florida.

Dr. Newton is highly rated in 21 conditions, according to our data. His clinical expertise encompasses Glioma, Brain Tumor, Astrocytoma, and Glioblastoma.

He is actively involved in clinical research, co-authoring 52 peer reviewed articles and participating in 9 clinical trials. Dr. Newton is currently accepting new patients.

Specialties

Oncology

Licenses

Psychiatry & Neurology in OH

Hospital Affiliations

Uh Cleveland Medical Center
University Hospitals Portage Medical Center
Parma Community General Hospital
Uh St John Medical Center
Lake Health

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Buckeye Health Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
First Health
  • INSURANCE PLAN
  • MEDICARE PDP
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medical Health
  • HMO
  • PPO
Medical Mutual
  • HMO
  • PPO
SummaCare
  • HMO
  • PPO
Sunshine Health
  • EPO
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 12 Less Insurance Carriers -

Locations

AdventHealth Medical Group Neuro Oncology at
2501 N Orange Ave Ste 286, Orlando, FL 32804
Other Locations
Office
11000 Euclid Ave Rm 502, Cleveland, OH 44106

Additional Areas of Focus

Dr. Newton has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Neurofibromatosis Type 1 (NF1)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

Phase III Trial of Observation Versus Irradiation for a Gross Totally Resected Grade II Meningioma
Phase III Trial of Observation Versus Irradiation for a Gross Totally Resected Grade II Meningioma
Enrollment Status: Recruiting
Publish Date: June 25, 2026
Intervention Type: Other, Procedure, Radiation
Study Phase: Phase 3
A Randomized Phase II/III Open-Label Study of Ipilimumab and Nivolumab Versus Temozolomide in Patients With Newly Diagnosed MGMT (Tumor O-6-Methylguanine DNA Methyltransferase) Unmethylated Glioblastoma
A Randomized Phase II/III Open-Label Study of Ipilimumab and Nivolumab Versus Temozolomide in Patients With Newly Diagnosed MGMT (Tumor O-6-Methylguanine DNA Methyltransferase) Unmethylated Glioblastoma
Enrollment Status: Completed
Publish Date: April 22, 2026
Intervention Type: Other, Biological, Procedure, Drug, Radiation, Device
Study Drugs: Ipilimumab, Nivolumab, Temozolomide
Study Phase: Phase 2/Phase 3
LUNAR: Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure
LUNAR: Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure
Enrollment Status: Completed
Publish Date: March 18, 2026
Intervention Type: Drug, Device
Study Drug: Immune checkpoint inhibitors or docetaxel
Study Phase: Phase 3
Phase III Intergroup Study of Radiotherapy With Concomitant and Adjuvant Temozolomide Versus Radiotherapy With Adjuvant PCV Chemotherapy in Patients With 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma
Phase III Intergroup Study of Radiotherapy With Concomitant and Adjuvant Temozolomide Versus Radiotherapy With Adjuvant PCV Chemotherapy in Patients With 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma
Enrollment Status: Active_not_recruiting
Publish Date: January 22, 2026
Intervention Type: Drug, Radiation
Study Drugs: Concomitant Temozolomide (TMZ), Procarbazine, Adjuvant Temozolomide (TMZ), CCNU, Vincristine
Study Phase: Phase 3
Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150kHz) Concomitant With Gemcitabine and Nab-paclitaxel for Front-line Treatment of Locally-advanced Pancreatic Adenocarcinoma
Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150kHz) Concomitant With Gemcitabine and Nab-paclitaxel for Front-line Treatment of Locally-advanced Pancreatic Adenocarcinoma
Enrollment Status: Completed
Publish Date: January 21, 2026
Intervention Type: Drug, Device
Study Drugs: Gemcitabine, Nab-paclitaxel
Study Phase: Phase 3
Pivotal, Open-label, Randomized Study of Radiosurgery With or Without Tumor Treating Fields (TTFields) for 1-10 Brain Metastases From Non-small Cell Lung Cancer (NSCLC).
Pivotal, Open-label, Randomized Study of Radiosurgery With or Without Tumor Treating Fields (TTFields) for 1-10 Brain Metastases From Non-small Cell Lung Cancer (NSCLC).
Enrollment Status: Completed
Publish Date: October 31, 2025
Intervention Type: Device, Other
Study Phase: Phase 3
A Phase II Open-label Study Investigating the Efficacy, Safety and Pharmacokinetic Properties of OKN-007 Combined With Temozolomide in Patients With Recurrent Glioblastoma
A Phase II Open-label Study Investigating the Efficacy, Safety and Pharmacokinetic Properties of OKN-007 Combined With Temozolomide in Patients With Recurrent Glioblastoma
Enrollment Status: Completed
Publish Date: August 12, 2025
Intervention Type: Drug
Study Drugs: OKN-007, Temozolomide (TMZ)
Study Phase: Phase 2
A Phase 3 Randomized Double-blind, Controlled Study of ICT-107 With Maintenance Temozolomide (TMZ) in Newly Diagnosed Glioblastoma Following Resection and Concomitant TMZ Chemoradiotherapy
A Phase 3 Randomized Double-blind, Controlled Study of ICT-107 With Maintenance Temozolomide (TMZ) in Newly Diagnosed Glioblastoma Following Resection and Concomitant TMZ Chemoradiotherapy
Enrollment Status: Suspended
Publish Date: April 03, 2024
Intervention Type: Biological
Study Phase: Phase 3
ENGOT-ov50 / GOG-3029 / INNOVATE-3: Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 200kHz) Concomitant With Weekly Paclitaxel for the Treatment of Recurrent Ovarian Cancer
ENGOT-ov50 / GOG-3029 / INNOVATE-3: Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 200kHz) Concomitant With Weekly Paclitaxel for the Treatment of Recurrent Ovarian Cancer
Enrollment Status: Completed
Publish Date: March 29, 2024
Intervention Type: Device, Drug
Study Drug: Paclitaxel
Study Phase: Phase 3
View 8 Less Clinical Trials

52 Total Publications

Erratum: Evaluation of Regorafenib in Newly Diagnosed and Recurrent Glioblastoma: GBM AGILE Phase II/III Bayesian Randomized Platform Trial.
Erratum: Evaluation of Regorafenib in Newly Diagnosed and Recurrent Glioblastoma: GBM AGILE Phase II/III Bayesian Randomized Platform Trial.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: May 07, 2026
Similar Doctors
Expertise in
20
conditions
Expertise in
20
conditions
Referral may be required

AHMG Oncology And Hematology At Orlando

2501 N Orange Ave Ste 689, 
Orlando, FL 
 (0.1 miles away)
321-732-5395
Languages Spoken:
English, Hindi
See accepted insurances
Accepting New Patients
Offers Telehealth

Guru Sonpavde is an Oncologist practicing medicine in Orlando, Florida. Dr. Sonpavde is highly rated in 20 conditions, according to our data. His clinical expertise encompasses Urothelial Cancer, Bladder Cancer, Muscle Invasive Bladder Cancer, Orchiectomy, and Nephrectomy. Dr. Sonpavde is currently accepting new patients.

Expertise in
10
conditions
Expertise in
10
conditions
Referral may be required

AdventHealth Medical Group Oncology & Hematology At Orlando

2501 N Orange Ave Ste 689, 
Orlando, FL 
 (0.1 miles away)
386-406-8205
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Mark Socinski is an Oncologist practicing medicine in Orlando, Florida. Dr. Socinski is highly rated in 10 conditions, according to our data. His clinical expertise encompasses Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Lung Adenocarcinoma, EGFR Positive Lung Cancer, and Tissue Biopsy. Dr. Socinski is currently accepting new patients.

Expertise in
106
conditions
Expertise in
106
conditions
Referral may be required

AdventHealth Medical Group Oncology & Hematology At Orlando

2501 N Orange Ave Ste 689, 
Orlando, FL 
 (0.1 miles away)
754-255-6741
Languages Spoken:
English, Arabic, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Tarek Mekhail is an Oncologist practicing medicine in Orlando, Florida. Dr. Mekhail is highly rated in 106 conditions, according to our data. His clinical expertise encompasses Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), EGFR Positive Lung Cancer, Small Cell Lung Cancer (SCLC), and Tissue Biopsy. Dr. Mekhail is currently accepting new patients.

Frequently Asked Questions about Dr. Herbert B. Newton

How do I make an appointment with Dr. Herbert B. Newton?

You can book an appointment with Dr. Herbert B. Newton by calling their office at 407-303-2770. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Herbert B. Newton a top-rated expert for Glioma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Herbert B. Newton is classified as an Distinguished expert for Glioma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Herbert B. Newton specialize in?

While Dr. Herbert B. Newton is a Oncology, they have specific expertise in Glioma, Brain Tumor, and Astrocytoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Herbert B. Newton participate in research or clinical trials?

Yes. Dr. Herbert B. Newton has published 52 articles and abstracts on conditions like Glioma. You can view a list of Dr. Herbert B. Newton's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Herbert B. Newton accept my insurance?

Dr. Herbert B. Newton accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 407-303-2770 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Newton's expertise for a condition
ConditionClose
    View All 15 Distinguished Conditions
    View All 21 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile